5-bromo-N-(2-methyl-5-sulfamoylphenyl)furan-2-carboxamide | 314055-73-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-bromo-N-(2-methyl-5-sulfamoylphenyl)furan-2-carboxamide
• CAS: 314055-73-7
• 化学式: C₁₂H₁₁BrN₂O₄S
• 分子量: 359.2
• InChiKey: JENKKRRLJZWBTR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  111
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Methods for identifying active compounds
  申请人：Parrow Vendela

  公开号：US20050042691A1

  公开（公告）日：2005-02-24

  The present invention relates to methods for identifying agents that modulate the effect of cytokine class I receptor binding compounds, by inhibiting the interaction between the cytokine class I receptor and nuclear factors. The agents are useful for decreasing IGF-1 levels in a cell, and for the treatment of medical disorders caused by hormone dysregulation, such as growth hormone or prolactin dysregulation.

  本发明涉及通过抑制细胞因子 I 类受体与核因子之间的相互作用来确定调节细胞因子 I 类受体结合化合物效果的制剂的方法。这些制剂可用于降低细胞中的 IGF-1 水平，以及治疗由激素失调（如生长激素或催乳素失调）引起的内科疾病。
• Screening methods
  申请人：Parrow Vendela

  公开号：US20060188945A1

  公开（公告）日：2006-08-24

  The present invention relates to methods for the identification of modulators of cytokine class I receptors by determining whether a compound that binds to a cytokine class I receptor at a site different from the binding site of the naturally-occurring cytokine ligand is effective at modulating the amount of the cytokine class I receptor on the surface of the cell.

  本发明涉及细胞因子 I 类受体调节剂的鉴定方法，其方法是确定与细胞因子 I 类受体结合位点不同于天然细胞因子配体结合位点的化合物是否能有效调节细胞表面细胞因子 I 类受体的数量。
• METHODS FOR IDENTIFYING AGENTS, WHICH REGULATE CYTOKINES
  申请人：BIOVITRUM AB

  公开号：EP1639371A1

  公开（公告）日：2006-03-29
• US7285392B2
  申请人：——

  公开号：US7285392B2

  公开（公告）日：2007-10-23
• [EN] METHODS FOR IDENTIFYING AGENTS, WHICH REGULATE CYTOKINES<br/>[FR] PROCEDES POUR IDENTIFIER DES AGENTS REGULANT LES CYTOKINES
  申请人：BIOVITRUM AB

  公开号：WO2005001478A1

  公开（公告）日：2005-01-06

  The present invention relates to methods for identifying agents that modulate the effect of cytokine class I receptor binding compounds, by inhibiting the interaction between the cytokine class I receptor and nuclear factors. The agents are useful for decreasing IGF-1 levels in a cell, and for the treatment of medical disorders caused by hormone dysregulation, such as growth hormone or prolactin dysregulation.